Overall, our findings unravel that Sirt6 acts as a key modulator in epithelial to mesenchymal transition process, suggesting Sirt6 may be an attractive potential therapeutic target for idiopathic pulmonary fibrosis. This evidence concerns the gene SIRT6 and idiopathic pulmonary fibrosis.